While Castle Biosciences Inc has underperformed by -13.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CSTL rose by 22.03%, with highs and lows ranging from $35.84 to $16.97, whereas the simple moving average fell by -0.05% in the last 200 days.
On December 14, 2023, Guggenheim started tracking Castle Biosciences Inc (NASDAQ: CSTL) recommending Buy. A report published by Scotiabank on January 05, 2023, Initiated its previous ‘Sector Outperform’ rating for CSTL. Stephens also rated CSTL shares as ‘Overweight’, setting a target price of $59 on the company’s shares in an initiating report dated January 07, 2022. Lake Street Initiated an Buy rating on April 30, 2021, and assigned a price target of $94. KeyBanc Capital Markets initiated its ‘Overweight’ rating for CSTL, as published in its report on November 10, 2020. Canaccord Genuity’s report from December 27, 2019 suggests a price prediction of $35 for CSTL shares, giving the stock a ‘Buy’ rating. SVB Leerink also rated the stock as ‘Outperform’.
Analysis of Castle Biosciences Inc (CSTL)
Further, the quarter-over-quarter increase in sales is 39.50%, showing a positive trend in the upcoming months.
One of the most important indicators of Castle Biosciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 1.47% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.64, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CSTL is recording 392.86K average volume. On a monthly basis, the volatility of the stock is set at 6.83%, whereas on a weekly basis, it is put at 12.27%, with a loss of -8.60% over the past seven days. Furthermore, long-term investors anticipate a median target price of $41.00, showing growth from the present price of $26.15, which can serve as yet another indication of whether CSTL is worth investing in or should be passed over.
How Do You Analyze Castle Biosciences Inc Shares?
The Diagnostics & Research market is dominated by Castle Biosciences Inc (CSTL) based in the USA. When comparing Castle Biosciences Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 130.82, there is a growth in quarterly earnings of 130.00%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.11%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.00% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CSTL shares are owned by institutional investors to the tune of 92.00% at present.
